Navigation Links
Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
Date:12/17/2009

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

The new Special European Physician & Payer Forum report entitled Targeted Therapies for NSCLC: How High are the Barriers to Displacing Avastin in Europe? finds that Avastin, which is not recommended for use within the United Kingdom's National Health Service, is used more often for non-small-cell lung cancer in the first and second line in France and Germany than in Italy and Spain. However, over the next 12 months, surveyed oncologists in Italy and Spain expect to increase first-line use of targeted agents such as Avastin, OSI Pharmaceuticals/Roche/Chugai's Tarceva and AstraZeneca's Iressa. According to the report, Tarceva is the second-most commonly prescribed targeted therapy in the first line after Avastin.

While Avastin, Tarceva and Iressa have shown modest efficacy in select patient populations, other agents in late-stage development have struggled to reach the non-small-cell lung cancer drug market. Three targeted therapies -- Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux, AstraZeneca's Zactima and Pfizer's figitumumab -- experienced recent setbacks in ongoing Phase III clinical trials or in receiving approval from the European Medicines Agency.

"The landscape for non-small-cell lung cancer will shift over the next several years as oncologists and payers grapple with the role of maintenance/consolidation therapy, increasing uptake of targeted therapies in the first-line setting and with the potential launch of new biologic ag
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
5. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
6. European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient
7. A Drugs Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections
8. Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8
9. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Sysmex America, Inc., ... information systems technology, will feature an exhibit booth during ... Meeting and Clinical Lab Expo in ... "We are extremely excited to exhibit ... to interact with our customers and continue the dialogue ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation (Apex, ... Pressure Area Care sectors, announces that it is appealing the ... in Germany that found the ... notes that it has initiated invalidity challenges against various ResMed ... in counterattacking against trivial and junk patents. ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Apex Continues Fighting Against Patents to Free Up Competition 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory ... that it is a Bronze winner in the 35th Annual ... Through a Child's Eye and Silverado Resident Visits ... a Child's Eye , seven-year-old Mia Sandoval shares her experience ... a memory care community in Los Angeles. The feel-good video ...
(Date:7/29/2014)... 29, 2014 According to a new ... leading global authority in medical device market research, the ... to over $8 billion by 2018. This growth ... the transcatheter heart valve market, which is comprised of ... transcatheter mitral valve repair (TMVR) segments. , There are ...
(Date:7/29/2014)... 29, 2014 According to the New ... the recreational and the medicinal sectors is mirroring the ... becomes more accepted in mainstream culture, many are turning ... the traditional and more dangerous forms of smoking the ... quite the trend in legalized states such as Colorado ...
(Date:7/29/2014)... 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... to improve access to essential pain medications for people ... ACS, Treat the Pain initiative, this new partnership will ... HIV/AIDS services throughout the country. , Swaziland has ... than 26 percent of adults ages 15-49 infected. Many ...
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:OZ Naturals to Launch Its Products in the UK 2
... planned strategic growth that ... Lansing and Michigan, LANSING, Mich., Oct. 8 In ... Grand River, accommodate up to 500 new jobs for,Lansing and ... subsidiary Accident Fund Insurance Company of America announced,today it will ...
... MURRYSVILLE, Pa., Oct. 8 Dixtal Medical, Inc.,and ... that Dixtal Medical,has acquired the Novametrix pulse oximetry ... will be marketed under the,Dixtal/Novametrix brand pursuant to ... Novametrix, founded in 1978 and acquired,by Respironics in ...
... mean more estrogen, bringing higher odds for the illness, researchers ... and shape of a woman,s hips may affect her daughter,s ... The study of 6,370 Finnish women found that breast cancer ... mothers with relatively wide hips, and nearly seven times higher ...
... Brothers is proud to be the,leading supplier of Official ... extends over 90 years. The embroidered badges and awards,produced ... substances. As a global manufacturer, Lion Brothers maintains ... substances in any of its,manufacturing processes. Lion tests materials ...
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce ... 25. During a conference call on October 25 at ... executives will,address inquiries from investors and analysts. Investors ... a live,webcast of the call at http://www.bms.com/ir ...
... or useless, the appendix now appears to have a reason ... bacteria living in the human gut. , Drawing upon a ... postulate that the beneficial bacteria in the appendix that aid ... evacuates the intestines and emerge afterwards to repopulate the gut. ...
Cached Medicine News:Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 2Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 3Health News:Woman's Hips Might Indicate Daughter's Breast Cancer Risk 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 3
... Drug Interaction Principles is the number one ... , An understanding of drug interactions has ... Since publication of the first edition of ... pharmacopoeia - coupled with prolonged human life ...
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Updated for 2006 with more than 800 complete drug entries, this mobile reference provides instant access to all the drug information nurses need in day-to-day practice....
... ACM-8 loads and unloads two centrifuges with ... via Cap Recognition the tube type is ... batches of three 5 position racks into ... single centrifuge ACM can be offered for ...
Medicine Products: